Literature DB >> 2328191

The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man.

R K Verbeeck1, G R Loewen, J I MacDonald, R J Herman.   

Abstract

1. The single (250 and 500 mg) and multiple dose (250 and 500 mg twice daily for 15 days) pharmacokinetics of diflunisal were compared in young volunteers. 2. The plasma clearance of diflunisal was lowered significantly after multiple dose administration (5.2 +/- 1.2 and 4.2 +/- 0.7 ml min-1 for the 250 and 500 mg twice daily regimens, respectively) as compared with single dose administration 11.4 +/- 3.1 and 9.9 +/- 2.0 ml min-1 for the 250 and 500 mg single doses, respectively). 3. The partial metabolic clearances of diflunisal by acyl and phenolic glucuronide formation were lowered significantly (greater than 50%) after multiple dose administration. 4. The urinary recovery of diflunisal sulphate increased as a function of dose: 6.1 +/- 2.8 and 9.1 +/- 3.5% following the 250 and 500 mg single dose, respectively, and 10.9 +/- 3.1 and 15.9 +/- 3.6% following the 250 and 500 mg twice daily regimens. The partial metabolic clearance of diflunisal by sulphate conjugation was unchanged following multiple dose administration. 5. The plasma protein binding of diflunisal was concentration-dependent. Analysis of unbound plasma clearances of diflunisal showed that its total plasma clearance following 500 mg twice daily was affected by both saturable glucuronidation and concentration-dependent plasma binding.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328191      PMCID: PMC1380106          DOI: 10.1111/j.1365-2125.1990.tb03654.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Disposition and irreversible plasma protein binding of tolmetin in humans.

Authors:  M L Hyneck; P C Smith; A Munafo; A F McDonagh; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1988-07       Impact factor: 6.875

2.  Simultaneous determination of zomepirac and its major metabolite zomepirac glucuronide in human plasma and urine.

Authors:  P N Langendijk; P C Smith; J Hasegawa; L Z Benet
Journal:  J Chromatogr       Date:  1984-05-11

3.  Dose-dependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism.

Authors:  J H Lin; K F Hooke; K C Yeh; D E Duggan
Journal:  J Pharmacol Exp Ther       Date:  1985-11       Impact factor: 4.030

Review 4.  Drug metabolite kinetics.

Authors:  J B Houston
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

5.  Plasma protein binding and interaction studies with diflunisal, a new salicylate analgesic.

Authors:  R K Verbeeck; A Boel; A Buntinx; P J De Schepper
Journal:  Biochem Pharmacol       Date:  1980-02-15       Impact factor: 5.858

6.  Estimation of kinetic parameters from a two-point determination of the drug cumulation factor.

Authors:  T D Bjornsson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

7.  Diflunisal disposition and hypouricemic response in osteoarthritis.

Authors:  P J Meffin; P M Brooks; J Bertouch; J R Veenendaal; B J Harrington
Journal:  Clin Pharmacol Ther       Date:  1983-06       Impact factor: 6.875

8.  Assay methodology for quantification of the ester and ether glucuronide conjugates of diflunisal in human urine.

Authors:  D G Musson; J H Lin; K A Lyon; D J Tocco; K C Yeh
Journal:  J Chromatogr       Date:  1985-02-08

Review 9.  Review of the animal and clinical pharmacology of diflunisal.

Authors:  R O Davies
Journal:  Pharmacotherapy       Date:  1983 Mar-Apr       Impact factor: 4.705

10.  Salicylate clearance, the resultant of protein binding and metabolism.

Authors:  D E Furst; T N Tozer; K L Melmon
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

View more
  5 in total

1.  Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis.

Authors:  J I Macdonald; S M Wallace; V Mahachai; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Concentration-dependent plasma protein binding of flurbiprofen in the rat: an in vivo microdialysis study.

Authors:  P A Evrard; J Cumps; R K Verbeeck
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

3.  Studies on the renal excretion of the acyl glucuronide, phenolic glucuronide and sulphate conjugates of diflunisal.

Authors:  R G Dickinson; A R King; G E McKinnon; W D Hooper; M J Eadie; G K Herkes
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

4.  Diflunisal and its conjugates in patients with renal failure.

Authors:  R G Dickinson; R K Verbeeck; A R King; A C Restifo; S M Pond
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

5.  Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal.

Authors:  J I Macdonald; S M Wallace; R J Herman; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.